CRI study highlights CTLA-4's marquee role in PD-1/L1 combos — despite an increasingly troubled clinical profile
Yesterday, we offered up a look at the broad range of immuno-oncology studies now underway the world over, as gathered by researchers at the Cancer Research Institute for their second annual examination of the landscape. But before we turn the page, I thought it would be instructive to focus on one critical aspect of the report that has major implications for this booming R&D sector.
The CRI’s assessment not only breaks out the 2,250 PD-1/L1 studies now in the clinic — up by 748 trials from a year ago — they also break out which combos are most popular.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.